Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
04 2022
Historique:
revised: 08 12 2021
received: 21 09 2021
accepted: 10 12 2021
pubmed: 9 1 2022
medline: 20 4 2022
entrez: 8 1 2022
Statut: ppublish

Résumé

Previous prospective studies highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men. It is unclear whether this association is causal or explained by reverse causation or confounding. The aim is to examine the association between genetically predicted dairy intake and PD using two-sample Mendelian randomization (MR). We genotyped a well-established instrumental variable for dairy intake located in the lactase gene (rs4988235) within the Courage-PD consortium (23 studies; 9823 patients and 8376 controls of European ancestry). Based on a dominant model, there was an association between genetic predisposition toward higher dairy intake and PD (odds ratio [OR] per one serving per day = 1.70, 95% confidence interval = 1.12-2.60, P = 0.013) that was restricted to men (OR = 2.50 [1.37-4.56], P = 0.003; P-difference with women = 0.029). Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Previous prospective studies highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men. It is unclear whether this association is causal or explained by reverse causation or confounding.
OBJECTIVE
The aim is to examine the association between genetically predicted dairy intake and PD using two-sample Mendelian randomization (MR).
METHODS
We genotyped a well-established instrumental variable for dairy intake located in the lactase gene (rs4988235) within the Courage-PD consortium (23 studies; 9823 patients and 8376 controls of European ancestry).
RESULTS
Based on a dominant model, there was an association between genetic predisposition toward higher dairy intake and PD (odds ratio [OR] per one serving per day = 1.70, 95% confidence interval = 1.12-2.60, P = 0.013) that was restricted to men (OR = 2.50 [1.37-4.56], P = 0.003; P-difference with women = 0.029).
CONCLUSIONS
Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 34997937
doi: 10.1002/mds.28902
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

857-864

Subventions

Organisme : Medical Research Council
Pays : United Kingdom

Informations de copyright

© 2022 International Parkinson and Movement Disorder Society.

Références

Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol 2014;29:613-619.
Elbaz A. Prodromal symptoms of Parkinson's disease: implications for epidemiological studies of disease etiology. Rev Neurol (Paris) 2016;172:503-511.
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2019;4:186.
Mendelian Randomization of Dairy Consumption Working Group. Dairy consumption and body mass index among adults: Mendelian randomization analysis of 184802 individuals from 25 studies. Clin Chem 2018;64:183-191.
Mendelian Randomization of Dairy Consumption Working Group. Dairy intake and body composition and Cardiometabolic traits among adults: Mendelian randomization analysis of 182041 individuals from 18 studies. Clin Chem 2019;65:751-760.
Hartwig FP, Davey SG. Lactase persistence and body mass index: the contribution of Mendelian randomization. Clin Chem 2018;64:4-6.
Hartwig FP, Horta BL, Smith GD, de Mola CL, Victora CG. Association of lactase persistence genotype with milk consumption, obesity and blood pressure: a Mendelian randomization study in the 1982 Pelotas (Brazil) birth cohort, with a systematic review and meta-analysis. Int J Epidemiol 2016;45(5):1573-1587.
Yang Q, Lin SL, Yeung SLA, et al. Genetically predicted milk consumption and bone health, ischemic heart disease and type 2 diabetes: a Mendelian randomization study. Eur J Clin Nutr 2017;71:1008-1012.
Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755-764.
Shim H, Chasman DI, Smith JD, et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One 2015;10:e0120758.
Bergholdt HKM, Larsen MK, Varbo A, Nordestgaard BG, Ellervik C. Lactase persistence, milk intake, hip fracture and bone mineral density: a study of 97 811 Danish individuals and a meta-analysis. J Intern Med 2018;284:254-269.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091-1102.
Blauwendraat C, Iwaki H, Makarious MB, et al. Investigation of autosomal genetic sex differences in Parkinson's disease. Ann Neurol 2021;90:35-42.
Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 2017;49:1511-1516.
Elsworth B, Lyon M, Alexander T, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv 2020;2020.2008. 2010:244293.
Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. Eur J Epidemiol 2018;33:947-952.
Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife 2018;7:e34408.
Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 2016;32:3207-3209.
Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 2019;35:4851-4853.
Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015;31:3555-3557.
Zhang Z, Wang M, Yuan S, Larsson SC, Liu X. Genetically predicted milk intake and risk of neurodegenerative diseases. Nutrients 2021;13(8):2893.
Wang Y, Gao L, Lang W, et al. Serum calcium levels and Parkinson's disease: a Mendelian randomization study. Front Genet 2020;11:824.
Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role for vitamin D in Parkinson's disease: a Mendelian randomization study. Mov Disord 2017;32:1249-1252.
Kia DA, Noyce AJ, White J, et al. Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease. Ann Neurol 2018;84:191-199.
Olsson E, Byberg L, Höijer J, Kilander L, Larsson SC. Milk and fermented Milk intake and Parkinson's disease: cohort study. Nutrients 2020;12:2763.
Abbott RD, Ross GW, Petrovitch H, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology 2016;86:512-519.
Noyce AJ, Kia DA, Hemani G, et al. Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study. PLoS Med 2017;14:e1002314.
Heilbron K, Jensen MP, Bandres-Ciga S, et al. Unhealthy Behaviours and risk of Parkinson's disease: a Mendelian randomisation study. J Parkinsons Dis 2021;11(4):1981-1993.
Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol 2021;36:465-478.
Aslam H, Marx W, Rocks T, et al. The effects of dairy and dairy derivatives on the gut microbiota: a systematic literature review. Gut microbes 2020;12:1799533.
Hughes DA, Bacigalupe R, Wang J, et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat Microbiol 2020;5:1079-1087.
Bergholdt HK, Nordestgaard BG, Varbo A, Ellervik C. Milk intake is not associated with ischaemic heart disease in observational or Mendelian randomization analyses in 98 529 Danish adults. Int J Epidemiol 2015;44:587-603.
Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson disease. Neurology 2020;95:e2095-e2108.
Yin W, Löf M, Pedersen NL, Sandin S, Fang F. Mediterranean dietary pattern at middle age and risk of Parkinson's disease: a Swedish cohort study. Mov Disord 2021;36:255-260.

Auteurs

Cloé Domenighetti (C)

UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.

Pierre-Emmanuel Sugier (PE)

UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.

Ashwin Ashok Kumar Sreelatha (A)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Tubingen, Germany.

Claudia Schulte (C)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Sandeep Grover (S)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Tubingen, Germany.

Océane Mohamed (O)

UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.

Berta Portugal (B)

UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.

Patrick May (P)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.

Dheeraj R Bobbili (DR)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.

Milena Radivojkov-Blagojevic (M)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Peter Lichtner (P)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Andrew B Singleton (AB)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, Maryland, USA.
Center For Alzheimer's and Related Dementias, NIA, NIH, Bethesda, Maryland, USA.

Dena G Hernandez (DG)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, Maryland, USA.

Connor Edsall (C)

Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, Maryland, USA.

George D Mellick (GD)

Griffith Institute for Drug Discovery, Griffith University, Nathan, Queensland, Australia.

Alexander Zimprich (A)

Department of Neurology, Medical University of Vienna, Wien, Austria.

Walter Pirker (W)

Department of Neurology, Wilhelminenspital, Wien, Austria.

Ekaterina Rogaeva (E)

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.

Anthony E Lang (AE)

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.
Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
Krembil Brain Institute, Toronto, Ontario, Canada.

Sulev Koks (S)

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia.

Pille Taba (P)

Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia.
Neurology Clinic, Tartu University Hospital, Tartu, Estonia.

Suzanne Lesage (S)

Department of Neurologie, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Paris, France.

Alexis Brice (A)

Department of Neurologie, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Paris, France.

Jean-Christophe Corvol (JC)

Department of Neurologie, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Paris, France.
Department of Neurology, CIC Neurosciences, Assistance Publique Hôpitaux de Paris, Paris, France.

Marie-Christine Chartier-Harlin (MC)

University Lille, Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, Lille, France.

Eugénie Mutez (E)

University Lille, Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, Lille, France.

Kathrin Brockmann (K)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Angela B Deutschländer (AB)

Department of Neurology, Ludwig Maximilians University of Munich, München, Germany.
Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, Florida, USA.

Georges M Hadjigeorgiou (GM)

Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.

Efthimos Dardiotis (E)

Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece.

Leonidas Stefanis (L)

First Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Athina Maria Simitsi (AM)

First Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Enza Maria Valente (EM)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy.

Simona Petrucci (S)

UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy.
Department of Clinical and Molecular Medicine, University of Rome, Rome, Italy.

Stefano Duga (S)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Humanitas Clinical and Research Center, IRCCS, Milan, Italy.

Letizia Straniero (L)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Anna Zecchinelli (A)

Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milan, Italy.

Gianni Pezzoli (G)

Parkinson Institute, Fontazione Grigioni, Milan, Italy.

Laura Brighina (L)

Department of Neurology, San Gerardo Hospital, Monza, Italy.
Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy.

Carlo Ferrarese (C)

Department of Neurology, San Gerardo Hospital, Monza, Italy.
Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy.

Grazia Annesi (G)

Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy.

Andrea Quattrone (A)

Institute of Neurology, Magna Graecia University, Catanzaro, Italy.

Monica Gagliardi (M)

Institute of Molecular Bioimaging and Physiology National Research Council, Catanzaro, Italy.

Hirotaka Matsuo (H)

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.

Yusuke Kawamura (Y)

Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan.

Nobutaka Hattori (N)

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

Kenya Nishioka (K)

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

Sun Ju Chung (SJ)

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Yun Joong Kim (YJ)

Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.

Pierre Kolber (P)

Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

Bart P C van de Warrenburg (BPC)

Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.

Bastiaan R Bloem (BR)

Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.

Jan Aasly (J)

Department of Neurology, St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway.

Mathias Toft (M)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Lasse Pihlstrøm (L)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Leonor Correia Guedes (L)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN), Lisbon, Portugal.

Joaquim J Ferreira (JJ)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Soraya Bardien (S)

Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

Jonathan Carr (J)

Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

Eduardo Tolosa (E)

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Mario Ezquerra (M)

Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Pau Pastor (P)

Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Barcelona, Spain.
Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain.

Monica Diez-Fairen (M)

Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Barcelona, Spain.
Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain.

Karin Wirdefeldt (K)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Nancy L Pedersen (NL)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Caroline Ran (C)

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andrea C Belin (AC)

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andreas Puschmann (A)

Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital, Lund, Sweden.

Clara Hellberg (C)

Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital, Lund, Sweden.

Carl E Clarke (CE)

University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.

Karen E Morrison (KE)

Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, United Kingdom.

Manuela Tan (M)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

Dimitri Krainc (D)

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Lena F Burbulla (LF)

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Matt J Farrer (MJ)

Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.

Rejko Krüger (R)

Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval, Luxembourg.
Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Strassen, Luxembourg.
Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.

Thomas Gasser (T)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tubingen, Germany.

Manu Sharma (M)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Tubingen, Germany.

Alexis Elbaz (A)

UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH